CureVac N.V. (5CV.F)
EUR 2.72
(-2.01%)
EUR 2.72
(-2.01%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -260.16 Million EUR | -2.33% |
| 2022 | -249.02 Million EUR | 39.51% |
| 2021 | -411.71 Million EUR | -218.98% |
| 2020 | -129.07 Million EUR | -29.24% |
| 2019 | -99.87 Million EUR | -40.19% |
| 2018 | -71.24 Million EUR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -72.9 Million EUR | -2.82% |
| 2024 Q1 | -70.55 Million EUR | 16.44% |
| 2023 Q2 | -67.41 Million EUR | -17.41% |
| 2023 FY | -254.83 Million EUR | -2.33% |
| 2023 Q1 | -57.41 Million EUR | 55.41% |
| 2023 Q4 | -84.42 Million EUR | -73.43% |
| 2023 Q3 | -48.68 Million EUR | 27.79% |
| 2022 Q3 | -47.56 Million EUR | 17.39% |
| 2022 Q2 | -57.58 Million EUR | -281.53% |
| 2022 Q1 | -15.09 Million EUR | -679.6% |
| 2022 FY | -249.02 Million EUR | 39.51% |
| 2022 Q4 | -128.78 Million EUR | -170.74% |
| 2021 Q1 | -113.7 Million EUR | -98.43% |
| 2021 Q3 | -144.02 Million EUR | 5.28% |
| 2021 Q2 | -152.05 Million EUR | -33.73% |
| 2021 FY | -411.71 Million EUR | -218.98% |
| 2021 Q4 | -1.93 Million EUR | 98.66% |
| 2020 Q4 | -57.3 Million EUR | -55.56% |
| 2020 Q3 | -36.83 Million EUR | -257.92% |
| 2020 Q2 | -10.29 Million EUR | 56.85% |
| 2020 Q1 | -23.85 Million EUR | 33.73% |
| 2020 FY | -129.07 Million EUR | -29.24% |
| 2019 Q1 | -21.3 Million EUR | 0.0% |
| 2019 Q3 | -18.36 Million EUR | 0.0% |
| 2019 FY | -99.87 Million EUR | -40.19% |
| 2019 Q4 | -35.99 Million EUR | -96.02% |
| 2018 FY | -71.24 Million EUR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| BioNTech SE | 930.3 Million EUR | 127.966% |
| Biotest Aktiengesellschaft | 127 Million EUR | 304.856% |
| Biotest Aktiengesellschaft | 127 Million EUR | 304.856% |
| BRAIN Biotech AG | -8.27 Million EUR | -3042.493% |
| Formycon AG | 75.79 Million EUR | 443.251% |
| Heidelberg Pharma AG | -20.34 Million EUR | -1178.683% |
| Medigene AG | -16.17 Million EUR | -1508.252% |